Melanotan-II — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 6 sources[1,2,3,4,5,6].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled… | Women’s Health | 2016 |
| 2 | Analytical and forensic aspects of counterfeit peptide hormones | Drug Testing and Analysis | 2023 |
| 3 | Falsified Ozempic (semaglutide) pens: patient safety alert | MHRA Safety Alert | 2023 |
| 4 | Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions | Expert Review of Proteomics | 2019 |
| 5 | Related impurities in peptide medicines | Journal of Pharmaceutical and Biomedical Analysis | 2014 |
| 6 | Quality of peptide products obtained from unregulated online suppliers: an analytical survey | Journal of Pharmaceutical Sciences | 2024 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 0 | — |
| Evidence syntheses | 1 | Melanocortin receptor agonists: approved indications and… |
| Comment periods | 1 | Draft monograph: Melanotan-II |
| Indication assessments | 2 | Sexual dysfunction · Obesity |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27638896
- Carvalho M, Dinis-Oliveira RJ. Analytical and forensic aspects of counterfeit peptide hormones. Drug Testing and Analysis 2023;15(1):5–19. doi:10.1002/dta.3379
- Medicines and Healthcare products Regulatory Agency. Falsified Ozempic (semaglutide) pens: patient safety alert. MHRA Safety Alert 2023;Alert reference NatPSA/2023/012/MHRA. identifier not held by the Institute
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.